FDA Panel Rejects Vernakalant Bid for AF Cardioversion Indication FDA Panel Rejects Vernakalant Bid for AF Cardioversion Indication

An advisory panel voted 11 to 2 not to recommend the drug ' s approval cardioversion of atrial fibrillation. Most voting no agreed the drug works but said it had serious safety issues.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news